Dermira (NASDAQ:DERM) Cut to Hold at Needham & Company LLC

Dermira (NASDAQ:DERM) was downgraded by analysts at Needham & Company LLC from a “buy” rating to a “hold” rating in a report issued on Friday, The Fly reports.

Several other research analysts have also recently issued reports on DERM. HC Wainwright cut shares of Dermira from a “buy” rating to a “neutral” rating and set a $18.75 target price on the stock. in a report on Thursday. Leerink Swann cut their target price on shares of Dermira from $23.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Evercore ISI restated a “buy” rating on shares of Dermira in a report on Thursday, December 12th. BidaskClub cut shares of Dermira from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, ValuEngine upgraded shares of Dermira from a “strong sell” rating to a “sell” rating in a report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $18.59.

Shares of Dermira stock traded down $0.07 on Friday, hitting $18.72. The stock had a trading volume of 488,178 shares, compared to its average volume of 3,866,763. The company has a quick ratio of 6.63, a current ratio of 7.03 and a debt-to-equity ratio of 25.08. Dermira has a one year low of $5.25 and a one year high of $19.48. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -4.09 and a beta of 1.62. The stock’s 50-day simple moving average is $14.99 and its two-hundred day simple moving average is $9.59.

Dermira (NASDAQ:DERM) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.40) by $0.34. Dermira had a negative net margin of 256.08% and a negative return on equity of 583.07%. The firm had revenue of $11.53 million for the quarter, compared to analysts’ expectations of $11.07 million. As a group, equities analysts predict that Dermira will post -4.15 EPS for the current fiscal year.

In related news, Director Matthew K. Fust sold 3,000 shares of Dermira stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $12.00, for a total value of $36,000.00. Following the sale, the director now owns 8,051 shares in the company, valued at $96,612. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 12.40% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its holdings in Dermira by 2.6% in the third quarter. California State Teachers Retirement System now owns 73,649 shares of the biopharmaceutical company’s stock valued at $471,000 after acquiring an additional 1,857 shares in the last quarter. Vanguard Group Inc. lifted its position in Dermira by 10.2% during the second quarter. Vanguard Group Inc. now owns 2,333,482 shares of the biopharmaceutical company’s stock valued at $22,308,000 after buying an additional 216,449 shares during the period. California Public Employees Retirement System lifted its position in Dermira by 70.3% during the third quarter. California Public Employees Retirement System now owns 24,119 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 9,958 shares during the period. State Street Corp lifted its position in Dermira by 2.2% during the third quarter. State Street Corp now owns 942,061 shares of the biopharmaceutical company’s stock valued at $6,020,000 after buying an additional 20,671 shares during the period. Finally, Virtu Financial LLC purchased a new position in Dermira during the third quarter valued at $85,000. Institutional investors and hedge funds own 94.49% of the company’s stock.

About Dermira

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

See Also: Is a Roth IRA right for you?

The Fly

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.